6 results about "Human neutrophil" patented technology

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

The objective was to develop a novel neutrophil elastase measurement method that can measure neutrophil elastase with high sensitivity. [Solution] A method for measuring human neutrophil elastase in a sample is provided, comprising contacting the sample with two or more antibodies or antigen-binding fragments thereof that recognize different epitopes on a complex with human neutrophil elastase. A reagent or kit for immunological measurement of human neutrophil elastase is also provided, comprising two or more antibodies or antigen-binding fragments thereof that recognize different epitopes on a complex with human neutrophil elastase and its inhibitor.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The invention belongs to the technical field of medicine development, and discloses a compound with a function of degrading human neutrophil elastinase (NE) as well as a preparation method and application of the compound. Specifically, the invention discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a stereoisomer and a prodrug molecule thereof, the compound has an effect of degrading target protein NE in cells, and the compound shows wide pharmacological activity related to degradation of the target protein NE. The compound can be used for preparing medicines for preventing / treating target protein NE overexpression diseases or symptoms.

The invention provides preparation and application of a monoclonal antibody for diagnosis aiming at a human neutrophil lipocalin (HNL) neoepitope. Two new HNL protein conformational epitopes and a new HNL linear epitope are designed and provided, and the anti-HNL antibody which is combined with the new epitopes and has higher binding affinity and better binding specificity is obtained through screening. The anti-HNL antibody disclosed by the invention can be used for preparing an HNL detection reagent and a kit, has higher sensitivity and specificity when being used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and virus infection.